Predictive value of CHFR and MLH1 methylation in human gastric cancer

Gastric Cancer

Volumn 18, Issue 2, 2015, Pages 280-287

  Li, Yazhuo ^a,b   Yang, Yunsheng ^b   Lu, Youyong ^c   Herman, James G ^d   Brock, Malcolm V ^d   Zhao, Po ^b   Guo, Mingzhou ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemo sensitive marker; CHFR; DNA damage repair genes; DNA methylation; Gastric cancer; MGMT; MLH1; RASSF1A

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CHFR PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ADULT; AGED; CANCER STAGING; DNA METHYLATION; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENETICS; HUMAN; INTESTINAL NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PERITONEAL NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84929173745     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0370-2     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. Wang X, Yang Y, Xu C, Xiao L, Shen H, Zhang X, et al. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. Int J Gynecol Cancer. 2011;21:996–1003.
3. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 2003;63:8606–13.
4. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004;64:4244–50.
5. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, et al. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer. 2004;3:16.
6. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65:1141–5.
7. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74.
8. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009;8:48.
9. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296–307.
10. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.
11. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933–8.
12. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
13. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012;31:4567–76.
14. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–9.
15. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14–3-3 sigma gene is associated with 5′-CpG island hypermethylation in human cancers. Cancer Res. 2000;60:4353–7.
16. Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res. 2001;92:952–8.
17. Shigeishi H, Yokozaki H, Kuniyasu H, Nakagawa H, Ishikawa T, Tahara E, et al. No mutations of the Bub1 gene in human gastric carcinomas. Oncol Rep. 2001;8:791–4.
18. Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, Kodera Y, et al. Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res. 2006;26:1791–5.
19. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41:133–9.
20. Gao YJ, Xin Y, Zhang JJ, Zhou J. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol. 2008;14:5000–7.
21. Akiyama Y, Nakasaki H, Nihei Z, Iwama T, Nomizu T, Utsunomiya J, et al. Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers. Jpn J Cancer Res. 1996;87:595–601.
22. Tamura G, Sakata K, Maesawa C, Suzuki Y, Terashima M, Satoh K, et al. Microsatellite alterations in adenoma and differentiated adenocarcinoma of the stomach. Cancer Res. 1995;55:1933–6.
23. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999;59:1090–5.
24. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006;17(suppl 7):97–102.
25. Endoh Y, Tamura G, Ajioka Y, Watanabe H, Motoyama T. Frequent hypermethylation of the hMLH1 gene promoter in differentiated-type tumors of the stomach with the gastric foveolar phenotype. Am J Pathol. 2000;157:717–22.
26. Roa JC, Anabalón L, Roa I, Tapia O, Melo A, Villaseca M, et al. Promoter methylation profile in gastric cancer. Rev Med Chil. 2005;133:874–80.
27. Moura Lima E, Ferreira Leal M, Cardoso Smith Mde A, Rodríguez Burbano R, Pimentel de Assumpção P, Bello MJ, et al. DNA mismatch repair gene methylation in gastric cancer in individuals from northern Brazil. Biocell. 2008;32:237–43.
28. Li GM. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res. 1999;11:393–400.
29. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881–6.
30. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335–41.
31. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, et al. Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease-free survival. J Clin Oncol. 2000;18:87–93.
32. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–6.
33. 6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep. 2010;23(5):1269–76.
34. Lin R, Li X, Li J, Zhang L, Xu F, Chu Y, Li J. Long-term cisplatin exposure promotes methylation of the OCT1 gene in human esophageal cancer cells. Dig Dis Sci. 2013;58(3):694–8.
35. Nyce JW. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res. 1997;386(2):153–61.